Akili Has Received A Notice Of Allowance For U.S. Patent Application 17/890,478 Titled "Cognitive Platform For Deriving Effort Metric For Optimizing Cognitive Treatment (Using Data Computed With Artificial Neural Network Or Deep Learning Techniques)"
Portfolio Pulse from Benzinga Newsdesk
Akili has received a notice of allowance for its U.S. patent application 17/890,478, titled "Cognitive Platform for Deriving Effort Metric for Optimizing Cognitive Treatment (Using Data Computed with Artificial Neural Network or Deep Learning Techniques)". This development marks a significant step forward in the use of AI and deep learning in cognitive treatment optimization.
March 26, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akili's receipt of a notice of allowance for its patent application on optimizing cognitive treatment using AI and deep learning techniques could significantly enhance its product offerings and market position.
The allowance of this patent application is a critical step in protecting Akili's intellectual property in the field of cognitive treatment optimization using AI. This could lead to enhanced product offerings, potentially increasing the company's competitiveness and market share in the health technology sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90